C12N 2310/336
Modified g
Official title: Modified G
C12N2310/336 (Modified g) appears on 213 US grants and 261 published applications in this corpus.
Search patents in C12N- Granted patents
- 213
- Published applications
- 261
- Assignees
- 114
- Inventors
- 447
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 2 | 0 |
| 1996 | 8 | 0 |
| 1997 | 20 | 0 |
| 1998 | 15 | 0 |
| 1999 | 10 | 0 |
| 2000 | 10 | 0 |
| 2001 | 5 | 3 |
| 2002 | 13 | 5 |
| 2003 | 4 | 10 |
| 2004 | 2 | 4 |
| 2005 | 3 | 14 |
| 2006 | 6 | 10 |
| 2007 | 2 | 10 |
| 2008 | 1 | 8 |
| 2009 | 3 | 4 |
| 2010 | 9 | 12 |
| 2011 | 7 | 8 |
| 2012 | 8 | 5 |
| 2013 | 5 | 5 |
| 2014 | 4 | 6 |
| 2015 | 8 | 16 |
| 2016 | 8 | 24 |
| 2017 | 3 | 8 |
| 2018 | 6 | 11 |
| 2019 | 9 | 15 |
| 2020 | 7 | 12 |
| 2021 | 11 | 8 |
| 2022 | 8 | 9 |
| 2023 | 5 | 12 |
| 2024 | 4 | 9 |
| 2025 | 2 | 18 |
| 2026 | 3 | 15 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- MRNA 5′-end cap analogs modified within phosphate residues, RNA molecule incorporating the same, uses thereof and method of synthesizing RNA molecule or peptide29 Sep 2026US 12,747,261 B2Explorna Therapeutics Sp. z o.o.
- Shingles vaccines comprising a TLR9 agonist10 Mar 2026US 12,569,553 B2Dynavax Technologies Corporation
- Methods and compositions for treatment of polycystic kidney disease24 Feb 2026US 12,559,750 B2Regulus Therapeutics Inc.
- Inhibiting APE2 expression in a subject treated with a drug agent that causes increased APE2 expression4 Nov 2025US 12,460,207 B2The Cleveland Clinic Foundation
- Modified compounds and uses thereof25 Feb 2025US 12,234,447 B2Ionis Pharmaceuticals, Inc.
- Trem compositions and methods of use1 Oct 2026US 2026/0297575 A1Flagship Pioneering Innovations VI, LLC
- Modified iscb nucleases, modified guide rnas, and uses thereof24 Sep 2026US 2026/0286324 A1Aera Therapeutics, Inc.
- Antisense RNA (asRNA) Technology and Use Thereof24 Sep 2026US 2026/0286353 A11Globe Health Institute LLC
- RNAi Agents for Inhibiting Expression of Superoxide Dismutase 1 (SOD1), Compositions Thereof, and Methods of Use17 Sep 2026US 2026/0275351 A1Arrowhead Pharmaceuticals, Inc.
- Methods and Compositions for Treatment of Polycystic Kidney Disease27 Aug 2026US 2026/0250679 A1Regulus Therapeutics Inc.
Most cited
By later US patents
- N-2 substituted purines806US 5,459,255 AIsis Pharmaceuticals, Inc. · 1995
- Sugar modified oligonucleotides that detect and modulate gene expression641US 5,670,633 AIsis Pharmaceuticals, Inc. · 1997
- Oligonucleotides having phosphorothioate linkages of high chiral purity626US 5,587,361 AIsis Pharmaceuticals, Inc. · 1996
- Oligonucleotides containing N-2 substituted purines621US 5,587,469 AIsis Pharmaceuticals, Inc. · 1996
- Substituted purines and oligonucleotide cross-linking603US 5,681,941 AIsis Pharmaceuticals, Inc. · 1997